EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Prostate-Specific Membrane Antigen-Targeted Therapy in Prostate Cancer: History, Combination Therapies, Trials, and Future Perspective

Francesco Mattana iD, Lorenzo Muraglia iD, Antonio Barone, Marzia Colandrea iD, Yasmina Saker Diffalah, Silvia Provera, Alfio Severino Cascio, Emanuela Omodeo Salè, Francesco Ceci iD

Cancers · 25.04.2024 · 16 (9) · 1643

DOI: 10.3390/cancers16091643 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 25.04.2024. Verfasst von Francesco Mattana und 8 weiteren Autor:innen. Beteiligte Einrichtung: Division of Nuclear Medicine, IEO European Institute of Oncology IRCCS, 20141 Milan, Italy. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 62 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In the last decades, the development of PET/CT radiopharmaceuticals, targeting the Prostate-Specific Membrane Antigen (PSMA), changed the management of prostate cancer (PCa) patients thanks to its higher diagnostic accuracy in comparison with conventional imaging both in staging and in recurrence. Alongside molecular imaging, PSMA was studied as a therapeutic agent targeted with various isotopes. In 2021, results from the VISION trial led to the Food and Drug Administration (FDA) approval of [177Lu]Lu-PSMA-617 as a novel therapy for metastatic castration-resistant prostate cancer (mCRPC) and set the basis for a radical change in the future perspectives of PCa treatment and the history of Nuclear Medicine. Despite these promising results, primary resistance in patients treated with single-agent [177Lu]Lu-PSMA-617 remains a real issue. Emerging trials are investigating the use of [177Lu]Lu-PSMA-617 in combination with other PCa therapies in order to cover the multiple oncologic resistance pathways and to overcome tumor heterogeneity. In this review, our aim is to retrace the history of PSMA-targeted therapy from the first preclinical studies to its future applications in PCa.

Schlagwörter

Stichwörter der Autor:innen

PSMAlutetiumoncologyprostate cancerradioligand therapytargeted therapy

Autor:innen und Institutionen

  • Division of Nuclear Medicine, IEO European Institute of Oncology IRCCS, 20141 Milan, Italy.
  • Division of Nuclear Medicine, Humanitas IRCCS, 20141 Milan, Italy.
  • Division of Nuclear Medicine, Hospital Clínico Universitario Lozano Blesa, 50009 Zaragoza, Spain.
  • Division of Pharmacy, IEO European Institute of Oncology IRCCS, 20141 Milan, Italy.
  • Department of Oncology and Hemato-Oncology, University of Milan, 20122 Milan, Italy.

ORCID-Profile: Francesco Mattana, Lorenzo Muraglia, Marzia Colandrea, Francesco Ceci

Zitieren

APA

Mattana, F., Muraglia, L., Barone, A., Colandrea, M., Saker Diffalah, Y., Provera, S., Cascio, A. S., Omodeo Salè, E., & Ceci, F. (2024). Prostate-Specific Membrane Antigen-Targeted Therapy in Prostate Cancer: History, Combination Therapies, Trials, and Future Perspective. Cancers, 16(9), 1643. https://doi.org/10.3390/cancers16091643

Vancouver

Mattana F, Muraglia L, Barone A, Colandrea M, Saker Diffalah Y, Provera S, et al. Prostate-Specific Membrane Antigen-Targeted Therapy in Prostate Cancer: History, Combination Therapies, Trials, and Future Perspective. Cancers. 2024;16(9):1643. doi:10.3390/cancers16091643

BibTeX
@article{Mattana2024,
  author = {Mattana, Francesco and Muraglia, Lorenzo and Barone, Antonio and Colandrea, Marzia and Saker Diffalah, Yasmina and Provera, Silvia and Cascio, Alfio Severino and Omodeo Salè, Emanuela and Ceci, Francesco},
  title = {Prostate-Specific Membrane Antigen-Targeted Therapy in Prostate Cancer: History, Combination Therapies, Trials, and Future Perspective},
  journal = {Cancers},
  year = {2024},
  volume = {16},
  number = {9},
  pages = {1643},
  doi = {10.3390/cancers16091643}
}
Kostenlos starten →